ANDREW H. KANG, MD, BS

Goodman Professor of Medicine, Emeritus
Medicine-Rheumatology and
Director of Research,, Center of Excellence for Diseases of Connective Tissue

Office: G326 COLEMAN BUILDING
956 COURT AVENUE
MEMPHIS TN 381632116
Tel: (901) 448-5774
akang@uthsc.edu

Education

  • M.D., Harvard Medical School, Medicine
  • B.S., Wofford College Spartanburg, South Carolina, N/A

Research Description

Dr. Andrew Ho Kang has led other investigators from multidisciplinary fields of study and they have made several original contributions to the biology of connective tissue. Their most significant discovery has been to identify the particular protein in a person’s joints where faulty cells attack, causing inflammation and other rheumatoid arthritic symptoms. This has led Dr. Kang and his associates to research on two different ways to treat rheumatoid arthritis. Dr. Kang''s current NIH-funded research is on "20(OH)VitD3, T Cells, and Arthritis". The goal of this research is to investigate the mechanism of synergy between collagen peptides and 20(OH)VitD3 in suppression of autoimmune arthritis.

Research Keywords

connective tissue disease, Rheumatology, immunology, inflammation, arthritis, Rheumatoid Arthritis, collagen-induced arthritis,  altered peptide-ligands, and vitamin D3 in arthritis.

Research Interest/Specialty

Dr. Andrew Ho Kang''s research involves several fields of study and is concentrated in the field of Rheumatology and the biology of connective tissue diseases. He specializes in inflammatory factors involved in Rheumatoid Arthritis and ways to treat these. Current research is on "20(OH)VitD3, T Cells, and Arthritis".

Publications

  1. Park, JE, Rotondo, JA, Cullins, DL, Brand, DD, Yi, AK, Stuart, JM, Kang, AH, Myers, LK. Characterization of the Syk-Dependent T Cell Signaling Response to an Altered Peptide. J Immunol, 2016.
  2. Liu, X, Jiao, Y, Cao, Y, Deng, N, Ma, Y, Hasty, KA, Kang, A, Chen, H, Stuart, JM, Gu, W. Decreased expression levels of Ifi genes is associated to the increased resistance to spontaneous arthritis disease in mice deficiency of IL-1RA. BMC Immunol, 17 (1), 25, 2016.
  3. Myers, LK, Cullins, DL, Park, JE, Yi, AK, Brand, DD, Rosloniec, EF, Stuart, JM, Kang, AH. Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization. Clin Immunol, 160 (2), 188-97, 2015.
  4. Tang, B, Kim, S, Hammond, S, Cullins, DL, Brand, DD, Rosloniec, EF, Stuart, JM, Postlethwaite, AE, Kang, AH, Myers, LK. Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis. Arthritis Res Ther, 16 (1), R7, 2014.
  5. Park, JE, Cullins, D, Zalduondo, L, Barnett, SL, Yi, AK, Kleinau, S, Stuart, JM, Kang, AH, Myers, LK. Molecular basis for T cell response induced by altered peptide ligand of type II collagen. J Biol Chem, 287 (23), 19765-74, 2012.
  6. Kimata, M, Cullins, DL, Brown, ML, Brand, DD, Rosloniec, EF, Myers, LK, Stuart, JM, Kang, AH. Characterization of inhibitory T cells induced by an analog of type II collagen in an HLA-DR1 humanized mouse model of autoimmune arthritis. Arthritis Res Ther, 14 (3), R107, 2012.
  7. Zhou, B, Yuan, J, Zhou, Y, Ghawji, M, Deng, YP, Lee, AJ, Lee, AJ, Nair, U, Kang, AH, Brand, DD, Yoo, TJ. Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol, 141 (3), 328-37, 2011.
  8. Myers, LK, Cullins, DL, Brand, DD, Kleinau, S, Stuart, JM, Kang, AH. T cells stimulated with an analog peptide of type II collagen require the Fc receptor γ-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice. Arthritis Rheum, 63 (9), 2661-70, 2011.
  9. Rosloniec, EF, Cremer, M, Kang, AH, Myers, LK, Brand, DD. Collagen-induced arthritis. Curr Protoc Immunol, Chapter 15, Unit 15.5.1-25, 2010.
  10. Tang, B, Cullins, DL, Zhou, J, Zawaski, JA, Park, H, Brand, DD, Hasty, KA, Gaber, MW, Stuart, JM, Kang, AH, Myers, LK. Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II. Arthritis Res Ther, 12 (4), R136, 2009.
  11. Tang, B, Zhou, J, Park, JE, Cullins, D, Yi, AK, Kang, AH, Stuart, JM, Myers, LK. T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol, 133 (1), 145-53, 2009.
  12. Xiong, Q, Jiao, Y, Hasty, KA, Stuart, JM, Postlethwaite, A, Kang, AH, Gu, W. Genetic and molecular basis of quantitative trait loci of arthritis in rat: genes and polymorphisms. J Immunol, 181 (2), 859-64, 2008.
  13. Myers, LK, Tang, B, Rosioniec, EF, Stuart, JM, Kang, AH. An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol, 27 (4), 345-56, 2008.
  14. Sakurai, Y, Brand, DD, Tang, B, Rosloniec, EF, Stuart, JM, Kang, AH, Myers, LK. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther, 8 (5), R150, 2006.
  15. Warrington, KJ, Nair, U, Carbone, LD, Kang, AH, Postlethwaite, AE. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther, 8 (4), R136, 2006.
  16. Carbone, LD, Barrow, KD, Bush, AJ, Boatright, MD, Michelson, JA, Pitts, KA, Pintea, VN, Kang, AH, Watsky, MA. Effects of a low sodium diet on bone metabolism. J Bone Miner Metab, 23 (6), 506-13, 2005.